Bristol Myers Squibb CEO Christopher Boerner Reports Routine Award Vesting & Tax Withholding

Executive Summary

On November 3, 2026, Bristol Myers Squibb Co ($BMY) filed a Form 4 disclosing equity award vesting and related tax withholding for Chief Executive Officer and Director Christopher S. Boerner.

On November 1, 2026, Dr. Boerner acquired 3,370 shares of Common Stock pursuant to the vesting of Market Share Units (2,964 shares vested under Code M, plus an additional 406 shares under Code J reflecting a performance factor adjustment). Simultaneously, 1,724 shares were withheld by the issuer at $62.48 per share ($107,715.52 total value) to satisfy tax liabilities (Code F).

Transaction Breakdown

• Derivative Exercise / Vesting (Code M): 2,964 Market Share Units settled into common shares at $0.00.
• Performance Adjustment (Code J): 406 additional common shares earned due to performance multiplier payout.
• Tax Withholding (Code F): Disposition of 1,724 shares at $62.48 per share to cover statutory tax withholding requirements.
• Net Direct Shares Acquired: 1,646 shares.

Ownership Structure

• Direct Ownership: 23,097 shares of Common Stock following the transaction.
• Indirect Ownership: 125,439 shares held through a Spousal Lifetime Access Trust (SLAT).
• Remaining Derivative Holdings: 2,966 unvested Market Share Units maturing through November 1, 2027.

Market & Trading Significance

This transaction carries Low trading significance as it represents standard executive equity compensation vesting and mandatory tax withholding rather than open-market buying or selling activity.